Inato is a technology company.
Inato has raised $36.0M across 3 funding rounds.
Inato has raised $36.0M in total across 3 funding rounds.
Inato has raised $36.0M in total across 3 funding rounds.
Inato's investors include Cathay Innovation, Chris Gibson, Franck Le Ouay.
Inato is a Paris-based technology company founded in 2016 that builds an AI-powered platform connecting pharmaceutical companies, biotech firms, and Contract Research Organizations (CROs) with community-based research sites worldwide.[1][2][5] It serves the clinical research industry by enabling sites—particularly the 90% often overlooked outside top-tier networks—to self-select trials best suited for their patients, streamlining site selection, patient pre-screening, and enrollment to accelerate trials and boost diversity.[1][2] The platform tackles core problems like slow recruitment, limited site access, and lack of patient diversity, with strong growth including 120% year-over-year community site adoption and 210% pharma sponsor growth as of recent reports, plus partnerships with over half a dozen top-30 global pharma companies across 40+ countries and 70 disease areas.[2]
Inato was founded in 2016 (with some sources noting 2015) by Kourosh Davarpanah (CEO) and co-founders in Paris, France, emerging from a recognition of inefficiencies in clinical trial site selection.[1][5] Davarpanah and team identified how pharma sponsors typically engaged only the top 5% of sites, ignoring community hospitals and leaving 90% of potential sites sidelined, which limited patient diversity and slowed innovation.[2] A pivotal pivot two years prior to 2021 shifted focus to decentralizing research, empowering community investigators to proactively access pharma trials rather than waiting passively.[2] Early traction built rapidly in 2021 with over 1,200 new sites added, fueling expansion and fundraising efforts targeting 10,000 sites.[2] The company has raised $34M total, including a recent round, to scale globally while maintaining a remote-first culture with a Paris HQ.[3][5]
Inato rides the wave of AI in decentralized clinical trials, addressing pharma's diversity crisis amid regulatory pressures for inclusive patient recruitment and post-pandemic shifts to community-based research.[1][2] Timing aligns with generative AI advancements enabling scalable pre-screening, as traditional models waste 80-90% of sites and delay trials by months.[1][2] Market forces like rising trial costs ($2.6B average), talent shortages, and demands from underrepresented populations favor platforms like Inato's, which expands access to 10,000+ sites and influences ecosystems by partnering with CROs and top pharma to set standards for efficient, equitable research.[2][5] It shapes the landscape by democratizing innovation, potentially cutting recruitment times and boosting trial success rates in a $50B+ industry.
Inato is poised to dominate clinical trial marketplaces by scaling to 10,000 sites and deepening AI features like U.S.-wide pre-screening, fueled by its $34M funding and pharma alliances.[2][5] Trends in AI reasoning, regulatory diversity mandates, and decentralized trials will propel growth, evolving its influence from niche connector to essential infrastructure for global research. As it closes fundraising and hits adoption milestones, Inato could redefine patient access, turning overlooked sites into innovation hubs and accelerating medical breakthroughs for all.
Inato has raised $36.0M across 3 funding rounds. Most recently, it raised $20.0M Series A in March 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2023 | $20.0M Series A | Cathay Innovation, Chris Gibson, Franck Le Ouay | |
| Feb 1, 2020 | $14.0M Series A | Cathay Innovation, Chris Gibson, Franck Le Ouay | |
| Nov 1, 2017 | $2.0M Seed |